Boston Scientific expecting 20%-plus sales growth despite near-term absence from stent market.
This article was originally published in The Gray Sheet
Executive Summary
BOSTON SCIENTIFIC PROJECTING 20%-PLUS REVENUE GROWTH IN 1998 despite the negative top-line impact likely to stem from the firm's absence from the $1 bil. U.S. coronary stent market. The company, which generated sales of nearly $1.9 bil. in 1997, hopes to enter the stent market by June with the NIR ON Ranger stent system; a premarket approval application was submitted on Jan. 28 ("The Gray Sheet" Feb. 2, In Brief).
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.